Chutima Kunacheewa

Publication Activity (10 Years)

Years Active: 2021-2022
Publications (10 Years): 6

Top Topics

Chronic Lymphocytic Leukemia

Oxide Nanoparticles

Multiple Myeloma

Top Venues

Journal of medical case reports

Leukemia & lymphoma

Expert review of hematology

Cell transplantation

This page only lists publications with an associated author ORCID identifier.

Publications

Mohammed Alomari, Chutima Kunacheewa, Elisabet E Manasanch
The role of soluble B cell maturation antigen as a biomarker in multiple myeloma. Leukemia & lymphoma (2022)
Chutima Kunacheewa, Sattawut Wongwiangjunt, Sanya Sukpanichnant
Concurrent myasthenia gravis-related cervical thymoma in a patient with diffuse large B-cell lymphoma: a case report. Journal of medical case reports 16 (1) (2022)
Chutima Kunacheewa, Weerapat Owattanapanich, Chutirat Jirabanditsakul, Surapol Issaragrisil
Post-Transplant Cyclophosphamide and Thymoglobulin, a Graft-Versus-Host Disease Prophylaxis in Matched Sibling Donor Peripheral Blood Stem Cell Transplantations. Cell transplantation 29 (2021)
Elisabet E Manasanch, David Berrios, Eric Fountain, Catherine M Claussen, Tammy Chuang, Gregory Kaufman, Behrang Amini, Qaiser Bashir, Yago L Nieto, Muzaffar Qazilbash, Krina Patel, Sheeba K Thomas, Donna M Weber, Zuzana Berkova, Gokce Toruner, Pei Lin, Lei Feng, Hans C Lee, Robert Z Orlowski, Chutima Kunacheewa
Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies. British journal of haematology 192 (4) (2021)
Chutima Kunacheewa, Elisabet E Manasanch
The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact. Expert review of hematology (2021)
Elisabet E Manasanch, Chutima Kunacheewa, Catherine M Claussen, Hans C Lee, Sheeba K Thomas, Jill Gunther, Chelsea C Pinnix, Bouthaina S Dabaja, Behrang Amini, Raymond Alexanian, Robert Z Orlowski, Wenli Dong, Lei Feng, Donna M Weber
Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up. Blood cancer journal 11 (2) (2021)